Overview
- Inspire Medical reported third-quarter EPS of $0.38 versus a consensus loss of $0.19 on revenue of $224.501 million versus $220.467 million expected.
- The company raised FY2025 GAAP EPS guidance to $0.90–$1.00 and reaffirmed sales guidance of $900 million to $910 million.
- Shares jumped about 17% to trade near $86.46 after the results and updated outlook.
- Chief executive Tim Herbert said the quarter focused on transitioning to the Inspire V system and cited data showing enhanced performance for the device.
- Analysts recalibrated views with lower price targets despite supportive ratings, including Wells Fargo to $90 (upgrade to Overweight), J.P. Morgan to $82 (Neutral), Truist to $84 (Hold), RBC to $125 (Outperform), and Piper Sandler to $135 (Overweight).